Methods for detecting surgical drain fluid exosomes and uses thereof
AssigneeWashington University
InventorsJose Zevallos, Aadel Chaudhuri
Life of this patent
Estimating the term…
Abstract
The present disclosure encompasses methods to detect. quantify. and/or analyze various surgical drain fluid (SDF) exosomal biomarkers and the uses thereof to inform diagnosis of diseases. select patients for further diagnostic testing, and guide treatment decisions.
Claims39
A method for detecting an exosome-associated biomarker in a biological sample, the method comprising
- isolating extracellular vesicles from a surgical drain fluid;
- and
- detecting at least one biomarker produced in the extracellular vesicles.
The method of 28, wherein the ischemic disease is selected from the group consisting of acute ischemic injury, chronic and acute ischemic diseases, ischemic heart disease, ischemic vascular disease, ischemic colitis, mesenteric ischemia, Brain ischemia (e.g., stroke), acute or chronic limb ischemia, cutaneous ischemia, ischemic kidney, and the promotion of angiogenesis in tissues or organs in need thereof.
A method of measuring a treatment response in a subject having or at risk of having disease, the method comprising
- (a) quantifying, in a first SDF sample obtained from a subject, an exosome-associated biomarker;
- (b) administering a treatment to the subject;
- and
- (c) quantifying, in a SDF sample obtained from the subject after the treatment, the biomarker quantified in step (a);
- wherein no change or a decrease in the amount of the biomarker in the second sample, as compared to the first sample, indicates a positive treatment response, or wherein the amount of the biomarker increases in the second sample as compared to the first sample but the change is less than a change that occurs in a control group of subjects that have the disease but were not administered treatment.
A method of monitoring a subject having or at risk of having disease, the method comprising quantifying a biomarker according to any one of the proceeding claims, in a first SDF sample obtained from the subject and a second SDF sample obtained from the subject, wherein the second biological sample was obtained after the first biological sample;
- wherein an increase in the amount of the biomarker in the second sample as compared to the first sample indicates an increase in disease.
The method of any one of the preceeding claims, wherein an additional treatment is selected based on the quantity of the exosome-associated biomarker.
Dependencies are inferred from the claim text.